Pharmacologic issues in the critically ill

Clinics in Chest Medicine

Volumn 24, Issue 4, 2003, Pages 671-688

  Krishnan, Vidya ^a   Murray, Patrick ^b  

^a West Suburban Medical Center   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMIODARONE; AMITRIPTYLINE; ATRACURIUM; CYCLOSPORIN; DIAZEPAM; DIGOXIN; DOBUTAMINE; ENALAPRIL; ENALAPRILAT; ESMOLOL; GLYCERYL TRINITRATE; HEPARIN DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDRALAZINE; KETOCONAZOLE; LOOP DIURETIC AGENT; METOPROLOL; MORPHINE; NITRO DERIVATIVE; OMEPRAZOLE; OPIATE AGONIST; PHENYTOIN; PROCAINAMIDE; PROPOFOL; PROPRANOLOL; SALICYLIC ACID DERIVATIVE; SEDATIVE AGENT; TOBRAMYCIN; UNINDEXED DRUG;

AGE DISTRIBUTION; CENTRAL NERVOUS SYSTEM DEPRESSION; CRITICAL ILLNESS; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; ERROR; HUMAN; INTENSIVE CARE UNIT; PHARMACOGENOMICS; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA;

EID: 0345732111     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(03)00096-0     Document Type: Review

References (37)

1. Physicians' Desk Reference. 57th edition. Montvale (NJ): Economics Company; 2002.
2. Summer WR, Michael JR, Lipsky JJ. Initial aminoglycoside levels in the critically ill. Crit Care Med 1983;11(12):948-50.
3. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. New Engl J Med 2000;342(20):1471-7.
4. Tukey RH, Johnson EF. Molecular aspects of regulation and structures of the drug-metabolizing enzymes. In: Pratt WB, Taylor P, editors. Principles of drug action. 3rd edition. New York: Churchill Livingstone; 1990. p. 423-68.
5. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG. The pharmacological basis of therapeutics. 9th edition. New York: McGraw Hill; 1996.
6. Lennard MS. Genetically determined adverse drug reactions involving metabolism. Drug Saf 1993;9(1): 60-77.
7. Anthony M, Berg MJ. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics and pharmacogenetics: part 1. J Womens Health Gend Based Med 2002;11(7):601-15.
8. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc 2002;94(10 Suppl):1-26.
9. Flockhart D. Drug interactions and the cytochrome P450 system: the role of cytochrome P450 2C19. Clin Pharmacokinet 1995;29:45-52.
10. Relling MV, Cherrie J, Schell MJ, et al. Lower prevalence of the debrisoquin oxidative poor metabolism phenotype in American black versus white subjects. Clin Pharmacol Ther 1991;50:308-13.
11. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role for pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001;286(18):2270-9.
12. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348(6):529-37.
13. Lerena AL, Alm C, Dahl ML, et al. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992;14:92-7.
14. Freeman BD, Zehnbauer BA, McGrath S, Borecki I, Buchman TG. Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 2000;128(2):281-5.
15. Watkins PB. Drug metabolism by cytochrome P450 in the liver and small bowel. Gastroenterol Clin N Am 1992;21(3):511-25.
16. Vessel ES. Therapeutic lessons from pharmacogenetics. Ann Intern Med 1997;126:653-5.
17. Beyth RJ, Shorr RI. Principles of drug therapy in older patients: rational drug prescribing. Clin Geriatr Med 2002;18:577-92.
18. Beierle I, Meibohm B, Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 1999;37(11):529-47.
19. Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 1999;66(6):594-601.
20. Rudy AC, Liu Y, Brater C, Hall S. Stereoselective pharmacokinetics and inversion of (r)-ketoprofen in healthy volunteers. J Clin Pharmacol 1998;38:3S-10.
21. Morgan DJ, Smallwood RA. Clinical significance of pharmacokinetic models of hepatic elimination. Clin Pharmacokinet 1990;18:61-76.
22. Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong EL, Gin T. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001;47(4):421-9.
23. Shadklofsky SI, Israel BC, McClain CJ. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 1994;94(6):2209-14.
24. Muller CM, Scierka A, Stiller RL. Nitric oxide mediates hepatic cytochrome P450 dysfunction induced by endotoxin. Anesthesiology 1996;84(6):1435-42.
25. Blobner M, Kochs E, Fink H, Mayer B, Veihelmann A, Brill T, et al. Pharmacokinetics and pharmacodynamics of vecuronium in rates with systemic inflammatory response syndrome: treatment with NG-monomethyl-L-arginine. Anesthesiology 1999;91(4):999-1005.
26. Katzung BG. Basic and clinical pharmacology. 8th edition. New York: Lange Medical Books/McGraw Hill; 2001.
27. Keogh A, Spratt P, McCosker C, et al. Ketoconazole reduces the need for cyclosporine after cardiac transplantation. N Engl J Med 1995;333:628-33.
28. Flockhart D. Cytochrome P450 Drug Interaction Table. Available at: http://medicine.iupui.edu/flockhart/. Accessed on May 29, 2003.
29. Gupta E, Wang X, Ramirez J, Ratain MJ. Modulation of glucoronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol 1997;39(5):440-4.
30. Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993;341(8841):335-9.
31. Pronovost P, Wu AW, Dorman T, Morlock L. Building safety into ICU care. J Crit Care 2002;17(2):78-85.
32. Calabrese AD, Erstad BL, Brandl K, Barletta JF, Kane SL, Sherman DS. Medication administration errors in adult patients in the ICU. Intensive Care Med 2001;27:1592-8.
33. Anderson JG, Jay SJ, Anderson M, Hunt TJ. Evaluation of the capability of information technology to prevent adverse drug events: a computer simulation approach. J Am Med Inform Assoc 2002;9:479-90.
34. Delbanco S. Leaping into patient safety. Mich Health Hosp 2001;37(2):28-30.
35. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, hospital pharmacy staffing, and medication errors in United States hospitals. Pharmacotherapy 2002;22(2):134-47.
36. Kalogeropoulos D, Carson ER, Collinson PO. Clinical-HINTS: integrated intelligent ICU patient monitoring and information management system. Medical Informatics Europe 1997;22:906-10.
37. Murray P, Corbridge T. Critical care pharmacology. In: Hall JB, Schmidt GA, Wood LDH, editors. Principles of critical care. 2d edition. New York: McGraw-Hill Health Professions Division; 1998. p. 1527-51.